Apogee Therapeutics (APGE) Long-Term Investments (2024 - 2026)

Apogee Therapeutics (APGE) has reported Long-Term Investments for 3 consecutive years, with $198.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 18.0% year-over-year to $198.4 million; the TTM figure through Mar 2026 stood at $198.4 million (up 18.0% YoY), while the FY2025 annual figure was $172.7 million, down 17.91% from the prior year.
• Long-Term Investments grew to $198.4 million in Q1 2026 per APGE's latest filing, from $172.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $227.7 million in Q3 2024 and bottomed at $61.6 million in Q3 2025.
• Historically, Long-Term Investments has averaged $158.5 million across 3 years, with a median of $170.4 million in 2025.
• Annual changes were most pronounced in 2025 — Long-Term Investments plunged 72.95% — and 2026, when it grew 18.0%.
• Apogee Therapeutics' Long-Term Investments stood at $210.4 million in 2024, then slipped by 17.91% to $172.7 million in 2025, then gained by 14.83% to $198.4 million in 2026.
• Business Quant data shows APGE's Long-Term Investments at $198.4 million in Q1 2026, $172.7 million in Q4 2025, and $61.6 million in Q3 2025.